Nebulin (Budesonide)

Nebulin (budesonide) is an inhaled glucocorticoid that reduces airway inflammation in chronic respiratory diseases.

• Asthma: improves symptom control, reduces frequency of exacerbations, and enhances lung function in patients with persistent asthma when used regularly.
• Chronic obstructive pulmonary disease (COPD): decreases airway inflammation, helps prevent COPD exacerbations, and may improve exercise tolerance in stable COPD patients.
• Maintenance therapy: provides long‑term control of airway inflammation, supporting daily management strategies for chronic respiratory disease as prescribed by a healthcare professional.

• Budesonide binds to intracellular glucocorticoid receptors in airway epithelial and inflammatory cells, forming a complex that translocates to the nucleus and modulates gene transcription. This action suppresses the production of multiple pro‑inflammatory cytokines, chemokines, and adhesion molecules, leading to reduced recruitment of eosinophils, neutrophils and other inflammatory cells, thereby decreasing airway edema and hyper‑responsiveness. The localized delivery via inhalation maximizes pulmonary concentrations while limiting systemic exposure.

Inhaled budesonide may cause a range of adverse reactions, most of which are mild and related to the respiratory tract or local irritation.

Common Side Effects

• Hoarseness or voice change: mild alteration in vocal quality
• Oral thrush (candidiasis): fungal infection of the mouth and throat
• Cough or throat irritation: transient irritation after inhalation
• Headache: mild to moderate head discomfort

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rapid onset of hives, swelling, and breathing difficulty
• Paradoxical bronchospasm: sudden worsening of airway narrowing after use
• Adrenal suppression: reduced cortisol production with prolonged high‑dose therapy

Before prescribing Nebulin, clinicians should consider several precautionary measures to ensure safe use.

• Assess infection risk: avoid use during active respiratory infections unless benefits outweigh risks.
• Monitor growth in children: long‑term inhaled corticosteroids may affect growth velocity.
• Evaluate bone health: consider calcium and vitamin D supplementation for prolonged high‑dose therapy.
• Use mouth rinsing: advise patients to rinse mouth after inhalation to reduce oral candidiasis.
• Review concomitant medications: check for drugs that may increase systemic corticosteroid exposure.
• Store below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Budesonide can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic budesonide concentrations, raising risk of corticosteroid‑related adverse effects.
• Concomitant systemic corticosteroids: additive glucocorticoid activity can lead to adrenal suppression, fluid retention, and hyperglycemia.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, phenytoin, carbamazepine): may lower budesonide exposure, potentially reducing therapeutic effectiveness.
• Antifungal azoles (e.g., fluconazole, voriconazole): can modestly raise budesonide levels, requiring clinical monitoring.
• Diuretics (e.g., furosemide, thiazides): may potentiate hypokalemia if systemic corticosteroid exposure becomes significant.